ifosfamide has been researched along with Lymphocytopenia in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Major treatment-related adverse events were grade 3 or more hematologic toxicities, which included lymphopenia corresponding to dose-limiting toxicity." | 2.75 | Activity and safety of combination chemotherapy with methotrexate, ifosfamide, l-asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: a pilot study. ( Hosone, M; Isobe, Y; Katsuoka, Y; Komatsu, N; Oshimi, K; Shimizu, S; Sugimoto, K; Tsukune, Y; Yasuda, H, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsukune, Y | 1 |
| Isobe, Y | 1 |
| Yasuda, H | 1 |
| Shimizu, S | 1 |
| Katsuoka, Y | 1 |
| Hosone, M | 1 |
| Oshimi, K | 1 |
| Komatsu, N | 1 |
| Sugimoto, K | 1 |
1 trial available for ifosfamide and Lymphocytopenia
| Article | Year |
|---|---|
Activity and safety of combination chemotherapy with methotrexate, ifosfamide, l-asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Female; Hematologic Neopl | 2010 |